Matches in SemOpenAlex for { <https://semopenalex.org/work/W2598715439> ?p ?o ?g. }
Showing items 1 to 95 of
95
with 100 items per page.
- W2598715439 abstract "346 Background: Early surrogate endpoints of benefit in mUC phase 2 salvage therapy trials are necessary to identify promising drugs, particularly for checkpoint inhibitors where response and progression-free survival are inadequate. We developed a nomogram using prognostic variables from phase 2 trials of historical agents to estimate 12 month survival to which observed survival in single arm trials could be compared. Methods: Data were obtained from phase II trials of salvage therapy for mUC for survival and 5 prognostic factors: hemoglobin, performance status, liver metastasis, treatment-free interval and albumin. Patients (pts) were randomly allotted to discovery:validation (DIS:VAL) datasets in a 2:1 ratio. A nomogram was developed for estimating 12-month survival. Calibration plots were constructed in the VAL dataset by plotting estimated vs. observed 12-mo survival and data bootstrapped to assess performance. The nomogram was applied to external nonrandomized salvage therapy data: 1) retrospective pemetrexed data or 2) trials of atezolizumab: PCD4989g and IMvigor210. Results: Data were available from 340 pts receiving sunitinib (n = 77), everolimus (n = 45), docetaxel + vandetanib or placebo (n = 109), pazopanib (n = 42), paclitaxel (n = 36) and docetaxel (n = 31). Calibration and prognostic ability of the model was acceptable (c-index = 0.634, 95% CI = 0.596-0.652). Observed 12-month survival for pts on pemetrexed (n = 127, 23.5% [95% CI: 16.2%-31.7%]) were similar to nomogram-predicted survival (19% [95% CI: 16.5-21.5], P> 0.05), while observed result with atezolizumab (n = 403, 39.0% [95% CI: 34.1-43.9]) exceeded predicted result (24.6% [95% CI: 23.4-25.8], P< 0.001). Conclusions: Atezolizumab was associated with a significantly longer 12-mo survival compared to nomogram-predicted survival while pemetrexed was not. This nomogram incorporates baseline prognostic factors to provide expected 12-mo survival of phase 2 patient cohorts with which to compare observed survival, thereby providing a useful tool to quantify benefit in phase II studies while controlling for the impact of clinical variables." @default.
- W2598715439 created "2017-04-07" @default.
- W2598715439 creator A5047689900 @default.
- W2598715439 creator A5050435057 @default.
- W2598715439 creator A5052069729 @default.
- W2598715439 creator A5052194834 @default.
- W2598715439 creator A5052504518 @default.
- W2598715439 creator A5058849092 @default.
- W2598715439 creator A5063326703 @default.
- W2598715439 creator A5063838757 @default.
- W2598715439 creator A5064292088 @default.
- W2598715439 creator A5064884168 @default.
- W2598715439 creator A5067058978 @default.
- W2598715439 creator A5074756323 @default.
- W2598715439 creator A5080697469 @default.
- W2598715439 creator A5083331837 @default.
- W2598715439 creator A5088186279 @default.
- W2598715439 date "2017-02-20" @default.
- W2598715439 modified "2023-09-24" @default.
- W2598715439 title "Nomogram to assess benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials: Effect of atezolizumab on 12-month survival." @default.
- W2598715439 doi "https://doi.org/10.1200/jco.2017.35.6_suppl.346" @default.
- W2598715439 hasPublicationYear "2017" @default.
- W2598715439 type Work @default.
- W2598715439 sameAs 2598715439 @default.
- W2598715439 citedByCount "2" @default.
- W2598715439 countsByYear W25987154392018 @default.
- W2598715439 crossrefType "journal-article" @default.
- W2598715439 hasAuthorship W2598715439A5047689900 @default.
- W2598715439 hasAuthorship W2598715439A5050435057 @default.
- W2598715439 hasAuthorship W2598715439A5052069729 @default.
- W2598715439 hasAuthorship W2598715439A5052194834 @default.
- W2598715439 hasAuthorship W2598715439A5052504518 @default.
- W2598715439 hasAuthorship W2598715439A5058849092 @default.
- W2598715439 hasAuthorship W2598715439A5063326703 @default.
- W2598715439 hasAuthorship W2598715439A5063838757 @default.
- W2598715439 hasAuthorship W2598715439A5064292088 @default.
- W2598715439 hasAuthorship W2598715439A5064884168 @default.
- W2598715439 hasAuthorship W2598715439A5067058978 @default.
- W2598715439 hasAuthorship W2598715439A5074756323 @default.
- W2598715439 hasAuthorship W2598715439A5080697469 @default.
- W2598715439 hasAuthorship W2598715439A5083331837 @default.
- W2598715439 hasAuthorship W2598715439A5088186279 @default.
- W2598715439 hasConcept C126322002 @default.
- W2598715439 hasConcept C126894567 @default.
- W2598715439 hasConcept C141071460 @default.
- W2598715439 hasConcept C141341695 @default.
- W2598715439 hasConcept C143998085 @default.
- W2598715439 hasConcept C164465091 @default.
- W2598715439 hasConcept C203092338 @default.
- W2598715439 hasConcept C2776694085 @default.
- W2598715439 hasConcept C2780775027 @default.
- W2598715439 hasConcept C3019894029 @default.
- W2598715439 hasConcept C34626388 @default.
- W2598715439 hasConcept C535046627 @default.
- W2598715439 hasConcept C71924100 @default.
- W2598715439 hasConceptScore W2598715439C126322002 @default.
- W2598715439 hasConceptScore W2598715439C126894567 @default.
- W2598715439 hasConceptScore W2598715439C141071460 @default.
- W2598715439 hasConceptScore W2598715439C141341695 @default.
- W2598715439 hasConceptScore W2598715439C143998085 @default.
- W2598715439 hasConceptScore W2598715439C164465091 @default.
- W2598715439 hasConceptScore W2598715439C203092338 @default.
- W2598715439 hasConceptScore W2598715439C2776694085 @default.
- W2598715439 hasConceptScore W2598715439C2780775027 @default.
- W2598715439 hasConceptScore W2598715439C3019894029 @default.
- W2598715439 hasConceptScore W2598715439C34626388 @default.
- W2598715439 hasConceptScore W2598715439C535046627 @default.
- W2598715439 hasConceptScore W2598715439C71924100 @default.
- W2598715439 hasLocation W25987154391 @default.
- W2598715439 hasOpenAccess W2598715439 @default.
- W2598715439 hasPrimaryLocation W25987154391 @default.
- W2598715439 hasRelatedWork W2060824462 @default.
- W2598715439 hasRelatedWork W2149469912 @default.
- W2598715439 hasRelatedWork W2277355548 @default.
- W2598715439 hasRelatedWork W2549807178 @default.
- W2598715439 hasRelatedWork W2590467141 @default.
- W2598715439 hasRelatedWork W2745944456 @default.
- W2598715439 hasRelatedWork W2806048958 @default.
- W2598715439 hasRelatedWork W2947607708 @default.
- W2598715439 hasRelatedWork W2972150079 @default.
- W2598715439 hasRelatedWork W2988160220 @default.
- W2598715439 hasRelatedWork W2995265110 @default.
- W2598715439 hasRelatedWork W3011219085 @default.
- W2598715439 hasRelatedWork W3024263816 @default.
- W2598715439 hasRelatedWork W3034561225 @default.
- W2598715439 hasRelatedWork W3159643038 @default.
- W2598715439 hasRelatedWork W3186599945 @default.
- W2598715439 hasRelatedWork W3187777643 @default.
- W2598715439 hasRelatedWork W3201091812 @default.
- W2598715439 hasRelatedWork W3202648464 @default.
- W2598715439 hasRelatedWork W3211574185 @default.
- W2598715439 isParatext "false" @default.
- W2598715439 isRetracted "false" @default.
- W2598715439 magId "2598715439" @default.
- W2598715439 workType "article" @default.